Valeant Shares Have Record Day as Investors Get Relief, for Now

  • Shares rise a record 25 percent, bonds surge as well
  • Drugmaker maintains guidance, promises strategic overhaul

Valeant Maintains Full-Year Guidance Despite Profit Miss

Valeant Pharmaceuticals International Inc. shareholders are finally giving the drugmaker a chance, at least until next quarter.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.